Synchronous trifocal invasive breast carcinoma – a case report
Carcinoma de mama invasivo trifocal síncrono – um caso clínico

Mariana Souto Miranda*, Ângela Melo**, Rita Sousa***, Luis Sá****
Instituto Português de Oncologia, Coimbra

Abstract
We report the case of a 50-year-old female diagnosed with bilateral breast carcinoma. The patient was submitted to bilateral mastectomy with sentinel LN biopsy and immediate breast reconstruction. The histopathology diagnosed a trifocal bilateral breast carcinoma. The incidence of bilateral breast carcinoma is increasing. There are no clear treatment guidelines for BBC.

Keywords: Bilateral breast cancer, synchronous; Trifocal.

INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed malignancy and the leading cause of cancer death in women. Bilateral BC (BBC) is a rare presentation, representing 2-5% of all breast malignancies1. This is the case of a 50-year-old female with bilateral trifocal invasive BC.

CASE REPORT
A 50-year-old female presented with two small lumps on both breasts with a 12-month evolution. First menses at age 10, two pregnancies (first at age 27) and breastfed for two weeks. She used combined oral contraception for 20 years. No relevant medical history or family history of BC. She smokes 20 cigarettes a day.

On clinical examination, two solid breast lumps were palpated – in the upper inner quadrant of the right breast and in the lower inner quadrant of the left breast. A right axillary lymph-node (LN) was detected. General physical and systemic examinations were normal.

Mammography and ultrasonography revealed three lumps – one with 13 mm in the union of the upper quadrants of the right breast, other in right axillary extension with 15 mm and the third in the union of the lower quadrants of the left breast with 7 mm. Ultrasonography directed microbiopsies revealed an invasive lobular carcinoma in the upper quadrant of the right breast, Grade1 (G1), with estrogens receptor status (ER)-100%, progesterone receptor status (PR)-8%, no HER-2 overexpression and Ki-67 expression of 14%. On the axillary extension was an invasive BC, not otherwise specified (NOS), G1, with ER-100%, PR-100%, no HER-2 overexpression and Ki-67 expression of 13%. On the left breast the histology was invasive BC, NOS, G1, with ER-100%, PR-0%, no HER-2 overexpression and Ki-67 expression of 5%. Axillary LN cytology, through ultrasound guided fine needle aspiration, was negative for malignancy.

Complementary exams revealed serum levels of carcinoembryonic antigen raised – 7,41 ng/mL and normal cancer antigen 15-3. Compute tomography scan (CT), magnetic resonance imaging (MRI) and skeletal scintigram showed no distant metastization.

The tumors were classified in T2N0 in the right breast and T0N0 in the left breast (Figure 1). The patient was submitted to bilateral skin-sparing mastectomy with sentinel LN biopsy and immediate breast reconstruction with prosthetic implants. The postoperative period was uneventful, with good recovery.

Histopathology of the right breast confirmed an in-
Invasive lobular carcinoma, G1 with associated lobular carcinoma in situ and an invasive BC, NOS, G1 – pathologic stage pT1bN0 (sn). On the left breast, an invasive BC, NOS, G1 with an associated low grade ductal carcinoma in situ with solid pattern of 1.1cm – pathologic stage pT1cN0 (sn). On the right breast, the distance from the tumor of the upper quadrants to the margin was under 0.01mm, and postoperative radiotherapy was decided.

The patient did external beam radiotherapy into the right breast area (50 Gy in 25 fractions over 5 weeks) and is currently on adjuvant hormonal therapy with tamoxifen.

This patient underwent appropriate genetic counseling and testing for hereditary breast cancer which was negative.

Patient is on follow-up, without clinical or imaging signs of recurrence after 2 year.

**DISCUSSION**

Due to improved life expectancy after BC treatment and routine use of contra-lateral breast mammography in newly diagnosed BC, the incidence of BBC is increasing. The tumor in the contralateral breast can be synchronous (within 6 months of the primary tumor) or metachronous (afterwards). In our case, although symptoms started 12 months earlier, all tumors were diagnosed simultaneously. A tumor in contralate-
eral breast may be a second primary tumor or metastasis from the first tumor. Despite the existence of methods such as cDNA microarray, the criteria for the diagnosis of second primary BC proposed by Chaudary et al. in 1984 - demonstration of in situ disease in the contralateral tumor, both carcinomas with different histological types and different grades - have been the most widely accepted method to distinguish second primary lesion from metastatic lesion. Without widespread systemic metastases, contralateral BC are generally separate primary tumors, as defined in this report. Concordance rates of ER and PR status and Her2 expression between two tumors are usually higher than 80%. RS Saad et al. and Imyanitov et al. demonstrated that BBC can be clonally independent events, despite having similar characteristics. In our case, different histology suggested different primary tumors.

The etiology is not clearly defined but there are known risk factors for BBC. Women with a diagnosed BC have 2–6 greater relative risk of developing contralateral BC. Lobular histology is a recognized risk factor for BBC - in our case, the right breast had a lobular carcinoma but a different histology was diagnosed in the left breast. Bilaterality is more commonly seen in cases with Her2 overexpression. In one study, Her2 overexpression was found in 71% against 35% in unilateral cancers. In another, Her2 was overexpressed in 44% of all bilateral tumor tissues, regardless of the first and second tumors, higher than the HER2 positivity rate of 26% in unilateral BC – this case showed no HER2 overexpression. Other risk factors include family history, genetic predisposition, younger age at diagnosis and nulliparity. Age was considered the most important predictor for contralateral BC - the earlier a woman develops a first BC, the higher the risk of developing a contralateral tumor. Because of her bilateral breast cancer at a young age, she met the National Comprehensive Cancer Network (NCCN) criteria for BRCA1/2 mutation testing. Key criteria for hereditary cancer risk evaluation are breast cancer diagnosed before the age of 50, triple-negative breast cancer diagnosed before 60, two or more primary breast cancers, invasive ovarian or fallopian tube cancer, or peritoneal cancer, male breast cancer, Ashkenazi Jewish ethnicity.

There are no clear treatment guidelines for BBC, the optimal surgical management is not well defined. The majority of patients undergo bilateral mastectomy. Breast conservation is rarely chosen due to stress from the diagnosis. For patients who undergo breast-conserving surgery, the follow-up and risk of recurrence as well as the need for bilateral breast irradiation are all factors in decision making. MRI is recommended when breast conservation is planned, to rule out multifocality or multicentricity, more common in BBC. Adjuvant therapy is based on the higher risk tumor.

Survival in BBC is equivalent or moderately lower than unilateral BC but synchronous tumors have poorer survival than metachronous. Multifocality is not amongst prognostic factors in international BC guidelines, but recent studies associate BC multifocality with higher general mortality rates and lower survival.

**CONCLUSION**

We report the case of a woman with three different tumors simultaneously. Histology, grade, hormone receptor status, Her2 and Ki67 expression were different. These and the presence of associated in situ component exclude metastatic origin of these tumors. One tumor was clinically unapparent and detected during the diagnosis of the others, supporting the importance of complete imaging screening at primary diagnosis.

**REFERENCES**
